Publication

Deja Vu: EGF Receptors Drive Resistance to BRAF Inhibitors.

Girotti, Maria Romina
; 
Marais, Richard
Citations
Altmetric:
Abstract
Summary: The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation. Cancer Discov; 3(5); 487-90. ©2013 AACR.
Authors
Girotti, Maria Romina
Marais, Richard
Affiliation
Molecular Oncology Group, The Paterson Institute for Cancer Research, The University of Manchester, Manchester, United Kingdom.
Description
Date
2013-05
Publisher
Collections
All Paterson Institute for Cancer Research
Show all metadata
Keywords
Type
Article
Citation
Deja Vu: EGF Receptors Drive Resistance to BRAF Inhibitors. 2013, 3 (5):487-90 Cancer Discov
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/293993
Embedded videos